Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus
epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.